Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
OptiNose, Inc. reported three-month period ended March 31, 2024 results: revenue approximately $14.9 million in net revenue from sales of XHANCE, net income a net loss of approximately $14.1 million.
- Period
- three-month period ended March 31, 2024
- Revenue
- approximately $14.9 million in net revenue from sales of XHANCE
- Net income
- a net loss of approximately $14.1 million
- Result
- preliminary results
Exact text from the filing
For the three-month period ended March 31, 2024, the Company expects to report: • approximately $14.9 million in net revenue from sales of XHANCE; • approximately $21.7 of operating expenses, consisting of approximately $1.2 million of research and development expenses and approximately $20.5 million of selling, general and administrative expenses; • a loss from operations of approximately $8.1 million; and • a net loss of approximately $14.1 million.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
OptiNose, Inc. entered into Securities Purchase Agreement with purchasers named therein valued at aggregate gross proceeds expected to be approximately $55 million (effective 2024-05-08).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- purchasers named therein
- Value
- aggregate gross proceeds expected to be approximately $55 million
- Effective
- 2024-05-08
Exact text from the filing
On May 8, 2024, OptiNose, Inc. (the “Company”) entered into securities purchase agreements (the “Purchase Agreement”) pursuant to which it agreed to issue and sell to the purchasers named therein an aggregate of (i) 31,800,000 shares (the “Shares”) of the Company’s common stock (“Common Stock”) at a purchase price of $1.00 per Share and (ii) in lieu of shares of Common Stock to certain investors, pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 23,700,000 shares of Common Stock (the “Pre-Funded Warrant Shares” and, together with the Shares and the Pre-Funded Warrants, the “Securities”) at a price of $0.999 per Pre-Funded Warrant, which represents the per share price for the Shares less the $0.001 per share exercise price for each such Pre-Funded Warrant (the foregoing collectively referred to as the “Registered Direct Offering”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
OptiNose, Inc. entered into Third Amendment to Amended and Restated Note Purchase Agreement with BioPharma Credit PLC, as collateral agent, and the purchasers party thereto valued at waiver of going concern qualification, reduction of minimum cash from $30M to $20M, issuance of 4,68 (effective 2024-05-08).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- BioPharma Credit PLC, as collateral agent, and the purchasers party thereto
- Value
- waiver of going concern qualification, reduction of minimum cash from $30M to $20M, issuance of 4,68
- Effective
- 2024-05-08
Exact text from the filing
On May 8, 2024, the Company entered into a Third Amendment (the “Third Amendment”) to that certain Amended and Restated Note Purchase Agreement, dated November 21, 2022, and amended on March 5, 2024 and March 8, 2024, among the Company and its subsidiary, OptiNose US, Inc., BioPharma Credit PLC, as collateral agent, and the purchasers party thereto from time to time.
View on SEC.gov